This is different than the glps, directly targeting subcutaneous fat.
Link to an earlier paper on the treatment:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9384315/
"At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics."
Comments
This is different than the glps, directly targeting subcutaneous fat.
Link to an earlier paper on the treatment: https://pmc.ncbi.nlm.nih.gov/articles/PMC9384315/ "At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics."